Aptamers are short single-stranded DNA or RNA oligonucleotides that fold into 3D structures and bind specific targets. In this review abstract, they are presented as delivery agents with potential to cross the BBB.
First-pass extracted concept
aptamers
Candidate: concept label5 source documents6 linked claims
Live refresh every 5sNext refresh in 5s
Extracted Explainers
What the tool is doing
Resources required
What problem it solves
Evidence Snippets
Aptamers, short single-stranded DNA or RNA oligonucleotides that can fold into unique 3D shapes and bind to specific target molecules, offer high affinity and specificity, low immunogenicity, and promising BBB penetration via receptor-mediated transcytosis targeting receptors such as the transferrin receptor (TfR) and low-density lipoprotein receptor-related protein 1 (LRP1).
We then assess recent progress in recognition elements, such as antibodies, aptamers, and enzymes, emphasizing not only their strengths but also their limitations and vulnerability to off-target interactions.
next-generation biorecognition elements, including aptamers
innovative delivery vehicles, including aptamers, peptides, and nanoparticles
Special attention is given to advanced affinity reagents, including aptamers, synthetic peptides, and antibody mimetics, which enhance biosensor specificity, stability, and translational potential.
Supporting Sources
Linked Claims
The blood-brain barrier restricts therapeutic delivery to the central nervous system and hinders treatment of neurological disorders.
Recognition elements including antibodies, aptamers, and enzymes have strengths but also limitations and vulnerability to off-target interactions.
Since 2020, the LYTAC platform has expanded to include multiple lysosome-targeting receptor targeting techniques and delivery vehicles such as aptamers, peptides, and nanoparticles.
Quoted textsource-backed
Since its inception in 2020, the LYTAC platform has consistently progressed, incorporating several Lysosome-targeting receptor (LTR) targeting techniques and innovative delivery vehicles, including aptamers, peptides, and nanoparticles.
Aptamers offer high affinity and specificity, low immunogenicity, and promising blood-brain barrier penetration via receptor-mediated transcytosis targeting receptors such as transferrin receptor and LRP1.
The review covers substrate engineering, nanomaterial-enabled amplification, and next-generation biorecognition elements including aptamers, AMPs, PNAs, XNAs, and CRISPR systems for sepsis diagnostics.
Quoted textsource-backed
In this review, we synthesize advances across substrate engineering, nanomaterial-enabled amplification, and next-generation biorecognition elements, including aptamers, AMPs, PNAs, XNAs, and CRISPR systems
Aptamers, synthetic peptides, and antibody mimetics enhance biosensor specificity, stability, and translational potential.